A recent study shows that a component of the DNA primase enzyme acts as a reversible on/off switch for DNA binding and represents a fundamentally new method of communication between DNA-processing enzymes.
News: Genome Maintenance Research Program
Vanderbilt chemists have been awarded $7.2 million over the next five years from the National Cancer Institute to lead an initiative to better understand how a combination chemotherapy for breast cancer targets DNA.
A potential cancer drug aimed at enhancing the effectiveness of ionizing radiation in lung cancer patients is a step closer to development with funding support from the Small Business Innovation Research (SBIR) program.
Vanderbilt researchers have identified a previously undetected type of histone modification that may have implications for cancer and other conditions.
A recent study showing that protein called RADX helps regulate the process of DNA repair may help us better understand why some cancers are more or less resistant to certain therapies
Kimryn Rathmell, MD, PhD, Cornelius Abernathy Craig Professor of Medicine and director of the Division of Hematology and Oncology at Vanderbilt-Ingram Cancer Center (VICC), has received a grant to research the role of immunosuppression in the tumor microenvironment for kidney cancer.
A new study by W. Kimryn Rathmell, MD, PhD, and colleagues, reveals a gene mutation’s role in Von Hippel-Lindau syndrome, a genetically inherited disease which causes tumor growth in several organs.
W. Kimryn Rathmell, MD, PhD, Cornelius A. Craig Professor of Medicine and director of the Division of Hematology and Oncology at Vanderbilt University Medical Center (VUMC), has been elected to the nominating committee of the American Society of Clinical Oncology (ASCO).
The first line of defense against skin cancer is the ability to repair DNA damage caused by UV light. Walter J. Chazin, PhD, and colleagues investigated how XPA – a protein involved in the repair of certain DNA damage – interacts with DNA and the effects of several disease-associated mutations in XPA on its molecular structure and ability to bind DNA.
Radiation-induced pulmonary fibrosis — tissue scarring that can permanently impair lung function — limits the delivery of therapeutic radiation doses to non-small cell lung cancer. To develop strategies for preventing or reducing fibrosis, Michael Freeman, Ph.D., and colleagues are exploring the cell types and factors that contribute to the radiation-induced fibrotic response.